{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:51:02Z","timestamp":1772142662664,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10557-023-07502-8","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T08:02:26Z","timestamp":1692345746000},"page":"1327-1335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effect of Beta-Blocker on Long-Term Major Cardiovascular Events in High Atherosclerotic Risk Population"],"prefix":"10.1007","volume":"38","author":[{"given":"Nichanan","family":"Osataphan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamol","family":"Udol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khanchai","family":"Siriwattana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bancha","family":"Sukanandachai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siriluck","family":"Gunaparn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wachiranun","family":"Sirikul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3986-1951","authenticated-orcid":false,"given":"Arintaya","family":"Phrommintikul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2418-329X","authenticated-orcid":false,"given":"Wanwarang","family":"Wongcharoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"issue":"18","key":"7502_CR1","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u2013e1032.","journal-title":"Circulation"},{"issue":"36","key":"7502_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"4","key":"7502_CR3","first-page":"e362","volume":"127","author":"PT O'Gara","year":"2013","unstructured":"O'Gara PT, Kushner FG, Ascheim DD, et al. ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362\u2013425.","journal-title":"Circulation"},{"issue":"25","key":"7502_CR4","first-page":"e344","volume":"130","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, et al. AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):e344\u2013426.","journal-title":"Circulation"},{"issue":"7200","key":"7502_CR5","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","volume":"318","author":"N Freemantle","year":"1999","unstructured":"Freemantle N, Cleland J, Young P, Mason J, Harrison J. beta Blockade after myocardial infarction: systematic review and meta regression analysis. Bmj. 1999;318(7200):1730\u20137.","journal-title":"Bmj"},{"issue":"13","key":"7502_CR6","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jama.2012.12559","volume":"308","author":"S Bangalore","year":"2012","unstructured":"Bangalore S, Steg G, Deedwania P, et al. beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13):1340\u20139.","journal-title":"JAMA"},{"key":"7502_CR7","doi-asserted-by":"publisher","first-page":"i4801","DOI":"10.1136\/bmj.i4801","volume":"354","author":"E Puymirat","year":"2016","unstructured":"Puymirat E, Riant E, Aissaoui N, et al. beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016;354:i4801.","journal-title":"BMJ"},{"issue":"1","key":"7502_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/ehf2.13715","volume":"9","author":"T Fukase","year":"2022","unstructured":"Fukase T, Dohi T, Koike T, et al. Long-term impact of beta-blocker in elderly patients without myocardial infarction after percutaneous coronary intervention. ESC Heart Fail. 2022;9(1):545\u201354.","journal-title":"ESC Heart Fail"},{"issue":"16","key":"7502_CR9","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jcin.2016.05.048","volume":"9","author":"AA Motivala","year":"2016","unstructured":"Motivala AA, Parikh V, Roe M, et al. Predictors, Trends, and Outcomes (Among Older Patients >\/=65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry. JACC Cardiovasc Interv. 2016;9(16):1639\u201348.","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"7502_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.mayocp.2017.11.019","volume":"93","author":"T Tsujimoto","year":"2018","unstructured":"Tsujimoto T, Kajio H, Shapiro MF, Sugiyama T. Risk of All-Cause Mortality in Diabetic Patients Taking beta-Blockers. Mayo Clin Proc. 2018;93(4):409\u201318.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"7502_CR11","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/dom.12878","volume":"19","author":"T Tsujimoto","year":"2017","unstructured":"Tsujimoto T, Sugiyama T, Kajio H. Effects of beta-blockers on all-cause mortality in patients with type 2 diabetes and coronary heart disease. Diabetes Obes Metab. 2017;19(6):800\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"7502_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1524-6175.2005.04254.x","volume":"7","author":"SE Kjeldsen","year":"2005","unstructured":"Kjeldsen SE, Lyle PA, Kizer JR, et al. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. J Clin Hypertens (Greenwich). 2005;7(3):152\u20138.","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"7","key":"7502_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.4070\/kcj.2021.0395","volume":"52","author":"J Park","year":"2022","unstructured":"Park J, Han JK, Kang J, et al. The Clinical Impact of \u03b2-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention. Korean Circ J. 2022;52(7):544\u201355.","journal-title":"Korean Circ J"},{"key":"7502_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.amjcard.2021.10.049","volume":"165","author":"DN Silverman","year":"2022","unstructured":"Silverman DN, de Lavallaz JDF, Plante TB, et al. Beta-Blocker Use in Hypertension and Heart Failure (A Secondary Analysis of the Systolic Blood Pressure Intervention Trial). Am J Cardiol. 2022;165:58\u201364.","journal-title":"Am J Cardiol"},{"issue":"9","key":"7502_CR15","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1161\/CIRCULATIONAHA.105.595496","volume":"113","author":"B Williams","year":"2006","unstructured":"Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213\u201325.","journal-title":"Circulation"},{"issue":"7","key":"7502_CR16","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jacc.2016.03.610","volume":"68","author":"FH Messerli","year":"2016","unstructured":"Messerli FH, Rimoldi SF, Bangalore S, Bavishi C, Laurent S. When an Increase in Central Systolic Pressure Overrides the Benefits of Heart Rate Lowering. J Am Coll Cardiol. 2016;68(7):754\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"7502_CR17","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et al. 2017ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269\u2013324.","journal-title":"Hypertension"},{"issue":"15","key":"7502_CR18","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1136\/heartjnl-2022-322115","volume":"109","author":"D Ishak","year":"2023","unstructured":"Ishak D, Aktaa S, Lindhagen L, et al. Association of beta-blockers beyond 1 year after myocardial infarction and cardiovascular outcomes. Heart. 2023;109(15):1159\u201365.","journal-title":"Heart"},{"key":"7502_CR19","doi-asserted-by":"crossref","unstructured":"Arnold SV, Silverman DN, Gosch K, et al. Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction. JACC Heart Fail. 2023.","DOI":"10.1016\/j.jchf.2023.03.017"},{"issue":"8","key":"7502_CR20","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","volume":"100","author":"S Bangalore","year":"2007","unstructured":"Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100(8):1254\u201362.","journal-title":"Am J Cardiol"},{"issue":"2","key":"7502_CR21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1161\/01.HYP.37.2.250","volume":"37","author":"AM Sharma","year":"2001","unstructured":"Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis. Hypertension. 2001;37(2):250\u20134.","journal-title":"Hypertension"},{"issue":"9557","key":"7502_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369(9557):201\u20137.","journal-title":"Lancet"},{"issue":"1 Pt 1","key":"7502_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S0002-8703(00)90325-9","volume":"139","author":"MR Weir","year":"2000","unstructured":"Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J. 2000;139(1 Pt 1):174\u201383.","journal-title":"Am Heart J"},{"issue":"12","key":"7502_CR24","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1001\/jama.1990.03440120075040","volume":"263","author":"BM Psaty","year":"1990","unstructured":"Psaty BM, Koepsell TD, Wagner EH, LoGerfo JP, Inui TS. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA. 1990;263(12):1653\u20137.","journal-title":"JAMA"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-023-07502-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-023-07502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T02:04:28Z","timestamp":1735783468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-023-07502-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7502"],"URL":"https:\/\/doi.org\/10.1007\/s10557-023-07502-8","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"7 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Joint Research Ethics Committee and Ministry of Public Health, Thailand (Approval Number COA-JREC 004\/2011, date of approval 21 May 2011).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all patients prior to the commencement of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}